Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
Int J Psychiatry Med
; 54(2): 150-156, 2019 03.
Article
em En
| MEDLINE
| ID: mdl-30058466
ABSTRACT
OBJECTIVES:
Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We report the case of a female patient suffering from treatment-resistant Tourette syndrome.METHODS:
Guideline-directed antipsychotic treatment with risperidone and aripiprazole as well as pure delta-9-tetrahydrocannabinol had no significant effect on Tourette syndrome symptomatology.RESULTS:
Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale.CONCLUSIONS:
It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dronabinol
/
Canabidiol
/
Síndrome de Tourette
/
Moduladores de Receptores de Canabinoides
Tipo de estudo:
Guideline
Limite:
Adolescent
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article